Olaparib phase III SOLO-2 trial demonstrates significant PFS benefit in BRCA-mutated disease

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

Citius Oncology announced positive topline results from a completed investigator‑initiated phase I clinical trial conducted by University of Pittsburgh investigators. This study evaluated the direct T-regulatory cell depletion activity of Lymphir (denileukin diftitox‑cxdl) in combination with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda) in patients with recurrent or refractory gynecologic cancers, including ovarian and endometrial malignancies.

March 13, 2026

Vol.52 No.10

Clinical Roundup

ROSELLA phase III trial of relacorilant in platinum-resistant ovarian cancer meets OS primary endpoint

ROSELLA phase III trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer met its overall survival primary endpoint.

February 27, 2026

Vol.52 No.08

Clinical Roundup

Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

Ovarian cancer cells may quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better, a study published by Mayo Clinic researchers suggests.

February 20, 2026

Vol.52 No.07

Drugs & Targets

FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

FDA approved pembrolizumab, as well as pembrolizumab and berahyaluronidase alfa-pmph in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.

February 13, 2026

Vol.52 No.06

Drugs & Targets

FDA approves companion diagnostic for pembrolizumab for ovarian cancer

FDA has approved PD-L1 IHC 22C3 pharmDx, Code SK006m as the only FDA-approved companion diagnostic indicated to aid in identifying first-line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, whose tumors express PD-L1 and who may be eligible for treatment with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Drug combination kills OVCAR3 ovarian cancer cells, UNM researchers find

With vague symptoms and no screening test, ovarian cancer can be deadly. According to NCI’s Surveillance, Epidemiology and End Results program, 20,890 people will receive an ovarian cancer diagnosis in 2025 and of these, more than half will learn that their ovarian cancer has spread to distant organs.

December 19, 2025

Vol.51 No.46

Olaparib phase III SOLO-2 trial demonstrates significant PFS benefit in BRCA-mutated disease

YOU MAY BE INTERESTED IN

Positive topline results announced from phase I study of Lymphir + pembrolizumab in r/r gynecologic cancers

ROSELLA phase III trial of relacorilant in platinum-resistant ovarian cancer meets OS primary endpoint

Lung cancer drug offers a surprising new treatment against ovarian cancer, Mayo study finds

FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

FDA approves companion diagnostic for pembrolizumab for ovarian cancer

Drug combination kills OVCAR3 ovarian cancer cells, UNM researchers find

Renew today!

Subscriber content

Never miss an issue!

Login